간질환 진단 시장 규모, 점유율 및 동향 분석 보고서 : 진단 방법별, 질환별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Liver Disease Diagnostics Market Summary

The global liver disease diagnostics market size was valued at USD 40.5 billion in 2025 and is projected to grow from USD 43.2 billion in 2026 to USD 66.4 billion by 2033, at a CAGR of 6.3% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 43.1% in 2025. The growth is primarily driven by the increasing prevalence of chronic liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), viral hepatitis, liver fibrosis, cirrhosis, and hepatocellular carcinoma.

The adoption of non-invasive diagnostic technologies, molecular diagnostics, biomarker-based assays, and artificial intelligence-enabled imaging is strengthening early disease detection, improving diagnostic accuracy, and supporting informed clinical decision-making. These advancements, coupled with expanding liver disease screening programs, increasing investments in precision medicine, and continued product innovation by leading market participants, are expected to strengthen diagnostic capabilities and support sustained market growth.

Global Liver Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global liver disease diagnostics market report on the basis of diagnosis technique, disease, end-use, and region:

• Diagnosis Technique Outlook (Revenue, USD Billion, 2021 - 2033)
• Laboratory Tests
• Imaging
• Endoscopy
• Biopsy
• Others
• Disease Outlook (Revenue, USD Billion, 2021 - 2033)
• NAFLD
• NASH
• Fibrosis
• Cirrhosis
• HCC
• Others
• End Use Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospitals
• Laboratories
• Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Diagnosis Technique Segment
  • 1.2.2. Disease Segment
  • 1.2.3. End-use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Global Liver Disease Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of metabolic and chronic liver diseases
    • 3.2.1.2. Advancements in Diagnostic Technologies
    • 3.2.1.3. Increasing Awareness and Early Detection
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Advanced Diagnostics
    • 3.2.2.2. Limited Awareness in Developing Regions
  • 3.2.3. Market opportunity analysis
• 3.3. Global Liver Disease Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Global Liver Disease Diagnostics Market: Diagnosis Technique Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Liver Disease Diagnostics Market Diagnosis Technique Movement Analysis
• 4.3. Global Liver Disease Diagnostics Market Size & Trend Analysis, by Diagnosis Technique, 2021 to 2033 (USD Billion)
• 4.4. Imaging
  • 4.4.1. Imaging market estimates and forecasts 2021 to 2033 (USD Billion)
• 4.5. Laboratory Tests
  • 4.5.1. Laboratory Tests market estimates and forecasts 2021 to 2033 (USD Billion)
• 4.6. Endoscopy
  • 4.6.1. Endoscopy market estimates and forecasts 2021 to 2033 (USD Billion)
• 4.7. Biopsy
  • 4.7.1. Biopsy market estimates and forecasts 2021 to 2033 (USD Billion)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 5. Global Liver Disease Diagnostics Market: Disease Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Liver Disease Diagnostics Market Disease Movement Analysis
• 5.3. Global Liver Disease Diagnostics Market Size & Trend Analysis, by Disease, 2021 to 2033 (USD Billion)
• 5.4. NAFLD
  • 5.4.1. NAFLD market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.5. NASH
  • 5.5.1. NASH market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.6. Fibrosis
  • 5.6.1. Fibrosis market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.7. Cirrhosis
  • 5.7.1. Cirrhosis market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.8. HCC
  • 5.8.1. HCC market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.9. Others
  • 5.9.1. Others market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 6. Global Liver Disease Diagnostics Market: End-use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Liver Disease Diagnostics Market End-use Movement Analysis
  • 6.2.1. Global Liver Disease Diagnostics Market Size & Trend Analysis, by End-use, 2021 to 2033 (USD Billion)
• 6.3. Hospitals
  • 6.3.1. Hospitals market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.4. Laboratories
  • 6.4.1. Laboratories market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.5. Others
  • 6.5.1. Others market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 7. Liver Disease Diagnostics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Share Analysis, 2025
• 8.4. List of Key Certification Providers/Scheme Owners
• 8.5. Company Profiles/Listing
  • 8.5.1. Abbott
    • 8.5.1.1. Company overview
    • 8.5.1.2. Financial performance
    • 8.5.1.3. Product benchmarking
    • 8.5.1.4. Strategic initiatives
  • 8.5.2. F. Hoffmann-La Roche Ltd.
    • 8.5.2.1. Company overview
    • 8.5.2.2. Financial performance
    • 8.5.2.3. Product benchmarking
    • 8.5.2.4. Strategic initiatives
  • 8.5.3. Thermo Fisher Scientific Inc.
    • 8.5.3.1. Company overview
    • 8.5.3.2. Financial performance
    • 8.5.3.3. Product benchmarking
    • 8.5.3.4. Strategic initiatives
  • 8.5.4. Randox Laboratories Ltd
    • 8.5.4.1. Company overview
    • 8.5.4.2. Financial performance
    • 8.5.4.3. Product benchmarking
    • 8.5.4.4. Strategic initiatives
  • 8.5.5. Boston Scientific Corporation
    • 8.5.5.1. Company overview
    • 8.5.5.2. Financial performance
    • 8.5.5.3. Product benchmarking
    • 8.5.5.4. Strategic initiatives
  • 8.5.6. Laboratory Corporation of America Holdings
    • 8.5.6.1. Company overview
    • 8.5.6.2. Financial performance
    • 8.5.6.3. Product benchmarking
    • 8.5.6.4. Strategic initiatives
  • 8.5.7. Fujifilm Corporation
    • 8.5.7.1. Company overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. Horiba Medical
    • 8.5.8.1. Company overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product benchmarking
    • 8.5.8.4. Strategic initiatives
  • 8.5.9. Siemens Healthcare GmbH
    • 8.5.9.1. Company overview
    • 8.5.9.2. Financial performance
    • 8.5.9.3. Product benchmarking
    • 8.5.9.4. Strategic initiatives
  • 8.5.10. Quest Diagnostics
    • 8.5.10.1. Company overview
    • 8.5.10.2. Financial performance
    • 8.5.10.3. Product benchmarking
    • 8.5.10.4. Strategic initiatives